Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum(TM)

Business Wire July 14, 2021

Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 2, 2021

Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 18, 2021

Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical

Business Wire June 2, 2021

Sesen Bio Strengthens Senior Leadership Team

Business Wire June 1, 2021

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference

Business Wire May 27, 2021

Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 21, 2021

Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum(TM)

Business Wire May 10, 2021

Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum(TM)

Business Wire May 4, 2021

Sesen Bio to Host Conference Call to Review First Quarter 2021 Financial Results and Provide Business Update on Monday, May 10, 2021

Business Wire May 3, 2021

Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 16, 2021

Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity "Horizons in Oncology" Virtual Conference

Business Wire April 8, 2021

Sesen Bio Announces Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend "FOR" Proposal to Increase Authorized Shares

Business Wire April 7, 2021

Sesen Bio and Qilu Pharmaceutical Announce Approval of IND Application in China for Vicineum(TM)

Business Wire March 22, 2021

Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 22, 2021

Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company's Lead Product Candidate Vicineum(TM)

Business Wire March 15, 2021

Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum(TM)

Business Wire March 8, 2021

Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Company's Lead Product Candidate Vicineum(TM)

Business Wire March 2, 2021

Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum(TM)

Business Wire February 16, 2021

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide a Business Update

Business Wire February 12, 2021